Skip to main content
    V

    Vaxcyte Inc (PCVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $59.40
    -2.21 (-3.59%)

    Market Cap: $9.75B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Vaxcyte Inc (PCVX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vaxcyte (PCVX) has a market cap of $9.75B and an enterprise value of $9.63B. Its share count is up 9.33% from a year earlier.

    Total Valuation

    Enterprise value is 1.29% below the market cap, as cash exceeds debt.

    Market Cap$9.75B
    Enterprise Value$9.63B
    Latest price (Nov 17, 2026)$59.40

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.05% in the quarter ended Sep 30, 2026 and grew 9.72% a year over 2 years.

    Shares Outstanding148.91M
    Shares Change (YoY)+9.33%
    Shares Change (QoQ)+3.05%
    Share Count Growth (2Y CAGR)+9.72%

    Price Statistics

    The stock is up 22.00% over 52 weeks and trades 4.55% below its 50-day average.

    Beta (1Y)1.28
    52-Week Change+22.00%
    1-Month Change-6.72%
    3-Month Change-6.16%
    6-Month Change+21.77%
    5-Year Change+165.09%
    Total Return (1Y)+22.00%
    Total Return (3Y CAGR)+4.90%
    Total Return (5Y CAGR)+19.36%
    Return vs SPY (1Y)+8.37%
    Max Drawdown (1Y)-27.95%
    Max Drawdown (3Y)-76.22%
    Sharpe Ratio (1Y)0.34
    Correlation with SPY (1Y)0.33
    50-Day Average$62.23
    200-Day Average$57.75
    52-Week Range$42.40 to $90.75
    RSI (14 Days)43.0
    Average Volume (20 Days)1.76M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.56x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.56x
    Quick Ratio4.56x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -46.14% over the last 12 months, against a 5-year average of -26.74%.

    Return on Equity (ROE)-46.14%
    Return on Assets (ROA)-38.42%
    ROE (5Y Average)-26.74%
    ROA (5Y Average)-24.08%
    ROIC (5Y Average)-26.07%

    Scores

    PCVX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit$4.99M
    Operating Income-$1.23B
    Pretax Income-$1.15B
    Net Income-$1.15B
    Reported EPS (TTM)-$8.06

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 83.28% of the $2.99B in total assets.

    Cash and Equivalents$125.47M
    Total Debt$0
    Net Cash$125.47M
    Net Cash Per Share$0.84
    Working Capital$1.05B
    Shareholder Equity$2.49B
    Book Value Per Share$16.72
    Total Assets$2.99B
    Total Liabilities$499.92M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $12.41M of capital spending, operating cash flow left -$974.42M of free cash flow.

    Operating Cash Flow-$962.01M
    Capital Expenditures$12.41M
    Free Cash Flow-$974.42M
    FCF Per Share-$6.19
    Depreciation and Amortization$26.84M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+28.89%
    Tangible Book Per Share Growth (2Y CAGR)+28.89%

    Revenue and profit by year

    Dividends and Yields

    PCVX does not pay a dividend. Its free cash flow yield is -11.02%.

    FCF Yield-11.02%
    Buyback Yield-7.12%
    Shareholder Yield-7.12%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PCVX

    What is PCVX's market cap?

    Vaxcyte has a market cap of $9.75B. Its enterprise value, which adds debt and subtracts cash, is $9.63B.

    How many shares of PCVX are outstanding?

    Vaxcyte has 148.91M shares outstanding. The count is up 9.33% from a year earlier.

    Does PCVX pay a dividend?

    No. Vaxcyte does not pay a dividend.

    How much debt does PCVX have?

    Vaxcyte has $0 of total debt and $125.47M of cash and equivalents, a net cash position of $125.47M.